Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues
Open Access
- 3 October 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1007315
Abstract
Drug repositioning or repurposing is the process of discovering leading-edge indications for authorized or declined/abandoned molecules for use in different diseases. This approach revitalizes the traditional drug discovery method by revealing new therapeutic applications for existing drugs. There are numerous studies available that highlight the triumph of several drugs as repurposed therapeutics. For example, sildenafil to aspirin, thalidomide to adalimumab, and so on. Millions of people worldwide are affected by neurodegenerative diseases. According to a 2021 report, the Alzheimer’s disease Association estimates that 6.2 million Americans are detected with Alzheimer’s disease. By 2030, approximately 1.2 million people in the United States possibly acquire Parkinson’s disease. Drugs that act on a single molecular target benefit people suffering from neurodegenerative diseases. Current pharmacological approaches, on the other hand, are constrained in their capacity to unquestionably alter the course of the disease and provide patients with inadequate and momentary benefits. Drug repositioning–based approaches appear to be very pertinent, expense- and time-reducing strategies for the enhancement of medicinal opportunities for such diseases in the current era. Kinase inhibitors, for example, which were developed for various oncology indications, demonstrated significant neuroprotective effects in neurodegenerative diseases. This review expounds on the classical and recent examples of drug repositioning at various stages of drug development, with a special focus on neurodegenerative disorders and the aspects of threats and issues viz. the regulatory, scientific, and economic aspects.Keywords
This publication has 154 references indexed in Scilit:
- Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustineBMC Medicine, 2013
- Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug developmentNature Reviews Drug Discovery, 2011
- PREDICT: a method for inferring novel drug indications with application to personalized medicineMolecular Systems Biology, 2011
- The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathiesPharmacological Research, 2011
- Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomersNeurobiology of Disease, 2010
- Antiviral agents in Alzheimer’s disease: hope for the future?Therapeutic Advances in Neurological Disorders, 2010
- Replication of the LINGO1 gene association with essential tremor in a North American populationEuropean Journal of Human Genetics, 2010
- Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigmsTherapeutic Advances in Neurological Disorders, 2009
- The Effects of Amyloid Precursor Protein on Postsynaptic Composition and ActivityJournal of Biological Chemistry, 2009
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004